A5068977373- Bladder and Urothelial Cancer Treatments
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Multiple Myeloma Research and Treatments
- Chronic Lymphocytic Leukemia Research
- Hemoglobinopathies and Related Disorders
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Advanced Breast Cancer Therapies
- Renal and related cancers
- Breast Cancer Treatment Studies
- Renal cell carcinoma treatment
- Epigenetics and DNA Methylation
- PI3K/AKT/mTOR signaling in cancer
- Economic and Financial Impacts of Cancer
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Hematopoietic Stem Cell Transplantation
- Viral-associated cancers and disorders
- Neutropenia and Cancer Infections
- Fibroblast Growth Factor Research
- Eosinophilic Disorders and Syndromes
- Medication Adherence and Compliance
- COVID-19 and healthcare impacts
Mayo Clinic
2016-2024
Minnesota Oncology
2023-2024
University of Minnesota
2024
Mayo Clinic in Florida
2019-2023
University of Minnesota Health Maple Grove Clinics
2020-2023
Mayo Clinic in Arizona
2017-2022
WinnMed
2019-2021
University of Minnesota Medical Center
2017-2020
Albany Medical Center Hospital
2020
Fairview Health Services
2019
Pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, is humanized monoclonal antibody used in the treatment of metastatic or unresectable melanoma and advanced non-small lung cancer (NSCLC). We hereby report case pembrolizumab-induced uveitis to increase practitioner awareness. A 78-year-old woman presented with onset panuveitis after initiation pembrolizumab therapy for melanoma. The patient received three cycles every 21 days, during which her symptoms progressively worsened....
Zanubrutinib, a Bruton tyrosine kinase inhibitor, is an approved treatment for chronic lymphocytic leukemia (CLL). To compare zanubrutinib vs ibrutinib relapsed refractory (R/R) CLL by calculating the number needed to treat (NNT) avoid 1 progression or death and associated cost impact. An NNT analysis was conducted estimate of patients with R/R that need be treated prevent death. Clinical efficacy data were derived from ALPINE trial, 24-month progression-free survival (PFS) final trials used...
The treatment paradigm for urothelial carcinoma (UC), a common genitourinary cancer, has significantly expanded in recent years. Enfortumab vedotin, Nectin-4-targeted antibody-drug conjugate, was recently approved by the U.S. Food & Drug Administration patients with advanced or metastatic UC following chemotherapy and immunotherapy. Approval of enfortumab vedotin based on findings from EV-201 trial, which demonstrated objective response rates 44%. Patients treated should be monitored...
Background Melphalan is the most common conditioning regimen used prior to autologous stem cell transplant (ASCT); however, there are varying data on optimal melphalan timing for best safety and efficacy. Historically, ASCT consisted of 200 mg/m 2 day (D-2) (48 h ASCT), but many institutions have since adopted a protocol with administration 1 (D-1) (24 SCT) or split dosing over days. The has yet be determined. Methods In this single-center retrospective study, we analyzed outcomes patients...
"HSR24-133: Real-World (RW) Effectiveness of Erythropoiesis-Stimulating Agents (ESAs) After Luspatercept in Patients (pts) With Myelodysplastic Syndromes (MDS): A Retrospective Analysis a Large Healthcare Claims Database the United States" published on 05 Apr 2024 by National Comprehensive Cancer Network.
Bioinformatics is defined as the application of computational and analytical tools to collect interpret biological data. With advancement in technology research, a vast amount data being produced, necessitating large-scale storage processing capabilities. Sequencing instruments lack sufficient capacity. Cloud computing offers an efficient solution these challenges, with low management costs. involves storing accessing “over Internet,” providing scalable flexible system for addressing...
J U N E 2 0 3 ONCOLOGY and its website, CancerNetwork.com, provide oncologists with the practical, timely, clinical information they need to deliver highest level of care their patients.Expert authors peer review ensure quality CancerNetwork.